دورية أكاديمية
أعرض في EDS

Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis

التفاصيل البيبلوغرافية
العنوان: Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
المؤلفون: Matthew Dean, Min Jung Kim, Sharon Dimauro, Susan Tannenbaum, Garth Graham, Bruce T. Liang, Agnes S. Kim
المصدر: Cardio-Oncology, Vol 9, Iss 1, Pp 1-10 (2023)
بيانات النشر: BMC, 2023.
سنة النشر: 2023
المجموعة: LCC:Diseases of the circulatory (Cardiovascular) system
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Anthracycline, Chemotherapy, Cardiotoxicity, Biomarker, Troponin, Growth/differentiation factor-15, Diseases of the circulatory (Cardiovascular) system, RC666-701, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Background Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction. Methods This study examined the levels of cardiac and noncardiac biomarkers before, after the last dose of, and 3–6 months after completion of doxorubicin chemotherapy. Cardiac biomarkers included 5th generation high-sensitivity cardiac troponin T (cTnT), N-terminal pro-brain natriuretic peptide, growth/differentiation factor-15 (GDF-15), and soluble suppression of tumorigenesis-2 (sST2). Noncardiac biomarkers included activated caspase-1 (CASP-1), activated caspase-3, C-reactive protein, tumor necrosis factor-α, myeloperoxidase (MPO), galectin-3, and 8-hydroxy-2’-deoxyguanosine. Echocardiographic data (LVEF and LVGLS) were obtained at pre- and post-chemotherapy. Subanalysis examined interval changes in biomarkers among high (cumulative doxorubicin dose ≥ 250 mg/m2) and low exposure groups. Results The cardiac biomarkers cTnT, GDF-15, and sST2 and the noncardiac biomarkers CASP-1 and MPO demonstrated significant changes over time. cTnT and GDF-15 levels increased after anthracycline exposure, while CASP-1 and MPO decreased significantly. Subanalysis by cumulative dose did not demonstrate a larger increase in any biomarker in the high-dose group. Conclusions The results identify biomarkers with significant interval changes in response to anthracycline therapy. Further research is needed to understand the clinical utility of these novel biomarkers.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2057-3804
العلاقة: https://doaj.org/toc/2057-3804Test
DOI: 10.1186/s40959-023-00174-1
الوصول الحر: https://doaj.org/article/bd6e18f5f66049bea8385d85a4281718Test
رقم الانضمام: edsdoj.bd6e18f5f66049bea8385d85a4281718
قاعدة البيانات: Directory of Open Access Journals
ResultId 1
Header edsdoj
Directory of Open Access Journals
edsdoj.bd6e18f5f66049bea8385d85a4281718
1008
3
Academic Journal
academicJournal
1008.06359863281
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.bd6e18f5f66049bea8385d85a4281718&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doaj.org/article/bd6e18f5f66049bea8385d85a4281718 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=20573804&ISBN=&volume=9&issue=1&date=20230401&spage=1&pages=1-10&title=Cardio-Oncology&atitle=Cardiac%20and%20noncardiac%20biomarkers%20in%20patients%20undergoing%20anthracycline%20chemotherapy%20%E2%80%93%20a%20prospective%20analysis&id=DOI:10.1186/s40959-023-00174-1 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Matthew+Dean%22">Matthew Dean</searchLink><br /><searchLink fieldCode="AR" term="%22Min+Jung+Kim%22">Min Jung Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Sharon+Dimauro%22">Sharon Dimauro</searchLink><br /><searchLink fieldCode="AR" term="%22Susan+Tannenbaum%22">Susan Tannenbaum</searchLink><br /><searchLink fieldCode="AR" term="%22Garth+Graham%22">Garth Graham</searchLink><br /><searchLink fieldCode="AR" term="%22Bruce+T%2E+Liang%22">Bruce T. Liang</searchLink><br /><searchLink fieldCode="AR" term="%22Agnes+S%2E+Kim%22">Agnes S. Kim</searchLink> )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Cardio-Oncology, Vol 9, Iss 1, Pp 1-10 (2023) )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => BMC, 2023. )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Diseases of the circulatory (Cardiovascular) system<br />LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Anthracycline%22">Anthracycline</searchLink><br /><searchLink fieldCode="DE" term="%22Chemotherapy%22">Chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiotoxicity%22">Cardiotoxicity</searchLink><br /><searchLink fieldCode="DE" term="%22Biomarker%22">Biomarker</searchLink><br /><searchLink fieldCode="DE" term="%22Troponin%22">Troponin</searchLink><br /><searchLink fieldCode="DE" term="%22Growth%2Fdifferentiation+factor-15%22">Growth/differentiation factor-15</searchLink><br /><searchLink fieldCode="DE" term="%22Diseases+of+the+circulatory+%28Cardiovascular%29+system%22">Diseases of the circulatory (Cardiovascular) system</searchLink><br /><searchLink fieldCode="DE" term="%22RC666-701%22">RC666-701</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Abstract Background Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction. Methods This study examined the levels of cardiac and noncardiac biomarkers before, after the last dose of, and 3–6 months after completion of doxorubicin chemotherapy. Cardiac biomarkers included 5th generation high-sensitivity cardiac troponin T (cTnT), N-terminal pro-brain natriuretic peptide, growth/differentiation factor-15 (GDF-15), and soluble suppression of tumorigenesis-2 (sST2). Noncardiac biomarkers included activated caspase-1 (CASP-1), activated caspase-3, C-reactive protein, tumor necrosis factor-α, myeloperoxidase (MPO), galectin-3, and 8-hydroxy-2’-deoxyguanosine. Echocardiographic data (LVEF and LVGLS) were obtained at pre- and post-chemotherapy. Subanalysis examined interval changes in biomarkers among high (cumulative doxorubicin dose ≥ 250 mg/m2) and low exposure groups. Results The cardiac biomarkers cTnT, GDF-15, and sST2 and the noncardiac biomarkers CASP-1 and MPO demonstrated significant changes over time. cTnT and GDF-15 levels increased after anthracycline exposure, while CASP-1 and MPO decreased significantly. Subanalysis by cumulative dose did not demonstrate a larger increase in any biomarker in the high-dose group. Conclusions The results identify biomarkers with significant interval changes in response to anthracycline therapy. Further research is needed to understand the clinical utility of these novel biomarkers. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article )
Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2057-3804 )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://doaj.org/toc/2057-3804 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1186/s40959-023-00174-1 )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/bd6e18f5f66049bea8385d85a4281718" linkWindow="_blank">https://doaj.org/article/bd6e18f5f66049bea8385d85a4281718</link> )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.bd6e18f5f66049bea8385d85a4281718 )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1186/s40959-023-00174-1 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 10 [StartPage] => 1 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Anthracycline [Type] => general ) [1] => Array ( [SubjectFull] => Chemotherapy [Type] => general ) [2] => Array ( [SubjectFull] => Cardiotoxicity [Type] => general ) [3] => Array ( [SubjectFull] => Biomarker [Type] => general ) [4] => Array ( [SubjectFull] => Troponin [Type] => general ) [5] => Array ( [SubjectFull] => Growth/differentiation factor-15 [Type] => general ) [6] => Array ( [SubjectFull] => Diseases of the circulatory (Cardiovascular) system [Type] => general ) [7] => Array ( [SubjectFull] => RC666-701 [Type] => general ) [8] => Array ( [SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens [Type] => general ) [9] => Array ( [SubjectFull] => RC254-282 [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Matthew Dean ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Min Jung Kim ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sharon Dimauro ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Susan Tannenbaum ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Garth Graham ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bruce T. Liang ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Agnes S. Kim ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 04 [Type] => published [Y] => 2023 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 20573804 ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 9 ) [1] => Array ( [Type] => issue [Value] => 1 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Cardio-Oncology [Type] => main ) ) ) ) ) ) )
IllustrationInfo